Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, has appointed George Tidmarsh as new senior vice president, chief scientific officer and head of R&D.
Subscribe to our email newsletter
Dr Tidmarsh is expected to provide the strategic planning and leadership necessary for managing all of Spectrum’s scientific operations, including clinical research, medical and regulatory affairs, biostatistics and data management, and pharmaceutical operations.
Dr Tidmarsh is expected to report directly to the CEO. He has served as a consultant to Spectrum prior to his appointment.
Dr Tidmarsh has founded Horizon Pharma and Threshold Pharmaceuticals, taking Threshold public in 2005 and guiding Horizon to successful completion of its Phase 3 program.
Rajesh Shrotriya, chairman of the board of directors, president and CEO of Spectrum, said: “I have known George for more than eight years as a dedicated and passionate scientist who works diligently with the uncanny ability of remaining focused on the mission at hand while keeping the big picture in mind.
“During the short period that he has been at Spectrum he has already demonstrated his excitement, passion and qualities for thoroughness.”
Dr Tidmarsh said: “I am pleased to be working with Dr Shrotriya and the team he has assembled at Spectrum Pharmaceuticals. Spectrum’s two marketed cancer drugs, Zevalin and Fusilev, are complemented by a promising diversified portfolio of novel drugs, two of which, Apaziquone and Belinostat, are in registrational trials poised for New Drug Applications within the next two years.
“I am looking forward to working diligently towards helping accomplish corporate goals and helping improve the quality of life of cancer patients.”